FDA Announces Glucagon-Injecting Device Recall
Posted By Meyerkord & Meyerkord, LLC
The FDA has announced today that Novo Nordisk has made the decision to
recall six batches of the glucagon-injecting devices after it has been reported
that needles in the GlucaGen HypoKit have detached from the syringes.
A detachment of the needle was reported to Novo Nordisk by a customer
in Portugal and one from the United Kingdom. Once detached, the syringe
becomes unusable. Unmanaged or untreated hypoglycemia can lead to unconsciousness,
seizures, and death. The company researched and found that out of 71,215
devices, only an estimated four would be at risk of detaching in the United
States. This research includes kits distributed since February 15 of this
year. The recall covers six batches with an expiration of September 30, 2017.
While it can be extremely costly for a manufacturer to do a product recall,
it is pertinent to the consumers’ health and safety. GlucaGen HypoKit
is approved and is used in treating those with hypoglycemia, an abnormal
decrease in the blood sugar. Unmanaged or untreated hypoglycemia can lead
to unconsciousness, seizures, and death.
Meyerkord & Meyerkord, LLC are consumer advocates, we do not accept
defective product injuries or wrongful deaths. Consumers have sent the
message to big businesses that their negligence will not be accepted.
Were you aware that last year 5 of the 50 largest verdicts were for defective
products and compensation amounts were 52% greater? Here at Meyerkord
& Meyerkord, LLC our outstanding reputation has been formed by many
things, including the recovery of more than $350 million and having more
than 100 years combined experience. We welcome a consultation where you
can share your experience and ask any questions; one of our knowledgeable
attorneys will dedicate their expertise to you.
Contact our office today for a free no-obligation consultation.